The prevalence and burden of Rome IV bowel disorders of gut brain interaction in patients with non-alcoholic fatty liver disease: a cross-sectional study

[1]  P. Whorwell,et al.  The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome foundation global epidemiology study , 2023, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[2]  O. Palsson,et al.  Epidemiology of disorders of gut‐brain interaction in Belgium and differences between two language groups: Results from the Rome foundation global epidemiology study , 2023, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[3]  Shengtao Zhu,et al.  Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study , 2022, BMC Medicine.

[4]  P. Whorwell,et al.  The symptom burden of Irritable Bowel Syndrome in tertiary care during the COVID‐19 pandemic , 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[5]  P. Whorwell,et al.  Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence? , 2021, World journal of hepatology.

[6]  J Zhang,et al.  2019 global NAFLD prevalence - A systematic review and meta-analysis. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  A. Ford,et al.  British Society of Gastroenterology guidelines on the management of irritable bowel syndrome , 2021, Gut.

[8]  V. Athwal,et al.  Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications , 2021, Current Diabetes Reports.

[9]  E. Savarino,et al.  Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. , 2020, The lancet. Gastroenterology & hepatology.

[10]  H. Tilg,et al.  NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications , 2020, Gut.

[11]  B. Hanratty,et al.  Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies , 2020, PLoS medicine.

[12]  P. Whorwell,et al.  Stigma and irritable bowel syndrome: a taboo subject? , 2020, The lancet. Gastroenterology & hepatology.

[13]  G. K. Beyera,et al.  Health-care utilisation for low back pain: a systematic review and meta-analysis of population-based observational studies , 2019, Rheumatology International.

[14]  M. Zamani,et al.  Systematic review with meta‐analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome , 2019, Alimentary pharmacology & therapeutics.

[15]  J. Walters,et al.  Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study , 2019, PloS one.

[16]  R. Malekzadeh,et al.  A Comprehensive Look at Irritable Bowel Syndrome and its Associated Factors Considering the Rome IV Criteria: A Penalized Smoothly Clipped Absolute Deviation Regression Approach in the Pars Cohort Study , 2018, Middle East journal of digestive diseases.

[17]  Mark Hudson,et al.  Guidelines on the management of abnormal liver blood tests , 2017, Gut.

[18]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[19]  D. Rodríguez-Sanz,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[20]  A. Ford,et al.  Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  K. LevineGlenn,et al.  Infections and Asthma in the Pediatric Intensive Care Unit: Prevalence and Contribution to Disease Severity , 2016 .

[22]  P. Whorwell,et al.  Faecal incontinence—the hidden scourge of irritable bowel syndrome: a cross-sectional study , 2014, BMJ open gastroenterology.

[23]  G. Tarantino,et al.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease? , 2013, World journal of gastroenterology.

[24]  P. Bhuyan,et al.  Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India. , 2013, Tropical gastroenterology : official journal of the Digestive Diseases Foundation.

[25]  S. Calloway More than coincidence. , 2013, Journal of Christian nursing : a quarterly publication of Nurses Christian Fellowship.

[26]  Pedagógia,et al.  Cross Sectional Study , 2019 .

[27]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[28]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[29]  N. Tannenwald A taboo subject , 2006 .

[30]  M Dixon-Woods,et al.  Medical and lay views of irritable bowel syndrome. , 2000, Family practice.

[31]  P. Whorwell,et al.  The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress , 1997, Alimentary pharmacology & therapeutics.

[32]  T. P. Giddings Tests , 1928 .

[33]  S. Abdel-Aal,et al.  Nonalcoholic fatty liver disease among patients with irritable bowel syndrome: Prevalence and contribution to disease severity , 2018 .

[34]  Lin Chang,et al.  Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. , 2016, Gastroenterology.

[35]  M. Blachier,et al.  Report Title: The burden of liver disease in Europe: a review of available epidemiological data , 2013 .

[36]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[37]  Y. Katayama Bowel disorders. , 1990, Postgraduate medicine.